Analyst Rating Update on Teva Pharmaceutical Industries Limited (TEVA)

Teva Pharmaceutical Industries Limited (TEVA) has an average broker rating of 1.53, which is interpreted as a Buy, as rated by 18 equity analysts. Nonetheless, 12 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 2 other analysts advise a Buy. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.

Teva Pharmaceutical Industries Limited (TEVA) : The highest level Teva Pharmaceutical Industries Limited (TEVA) is projected to reach is $100 for the short term and the lowest estimate is at $55. The consolidated price target from 17 rating analysts who initiate coverage on the stock is $73.11 and the possibility the share price can swing is $9.81.

For the current week, the company shares have a recommendation consensus of Buy. Also, Equity analysts at the Brokerage firm HSBC upgrades its rating on Teva Pharmaceutical Industries Limited (NYSE:TEVA). The rating major has initiated the coverage with buy rating on the shares. Earlier, the shares were rated a Hold by the brokerage firm. The rating by the firm was issued on July 18, 2016.


Teva Pharmaceutical Industries Limited (NYSE:TEVA): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $52.64 and $52.54 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $53.89. The buying momentum continued till the end and the stock did not give up its gains. It closed at $53.57, notching a gain of 1.15% for the day. The total traded volume was 5,022,928 . The stock had closed at $52.96 on the previous day.

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.